With a new expansion coming online in Copenhagen in June 2023, AGC Biologics is offering more capacity in Europe for mammalian biologics projects using innovative single-use bioreactor technology. This is the latest in a string of new investments from the global CDMO to expand capacity and upgrade technology at its sites in Europe, Japan, and the United States. The expansion was featured in a recent issue of European Biotechnology Magazine.
AGC Biologics invested in an expansion and a new dedicated building to extend the Copenhagen site’s capabilities and more than double its single-use bioreactor mammalian cell-culture capacity. AGC Biologics is actively having discussions to fill this space now, with operations beginning in mid-2023.
New Mammalian Manufacturing Capacity
The new building will include four levels holding about 18,000 m2 distributed across manufacturing, quality control laboratories, and technical and warehouse areas. The production is focused on genetically modified organisms, biosafety level 1, and manufactured using single-use technology in dedicated clean rooms.
This state-of-the-art building will house 8 x 2000L single-use bioreactors and benefit from two separate downstream lines for mammalian-based clinical supply and commercial manufacturing, effectively doubling the company's capacity in Europe. It will also include 1 x 500L perfusion bioreactor.
AGC Biologics Copenhagen site
The Denmark-based site is one of the most active biologics facilities in the AGC Biologics network.
AGC Biologics runs multiple mammalian and microbial cGMP manufacturing lines at various scales and offers technological flexibility to meet drug product specifications.
The campus' core teams of scientists have been working together to develop and manufacture biologics for more than 20 years. The facility is one of the top CDMO sites in Medicon Valley and is ready to take on more projects.